PUBLISHER: DelveInsight | PRODUCT CODE: 1415485
PUBLISHER: DelveInsight | PRODUCT CODE: 1415485
DelveInsight's "Non-Alcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology, and the Non-Alcoholic Steatohepatitis (NASH) market trends in Japan.
The Non-Alcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted in Japan, Non-Alcoholic Steatohepatitis (NASH) market size from 2019 to 2032. The report also covers current Non-Alcoholic Steatohepatitis (NASH) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
NASH is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. A complex activity between airway inflammation and remodeling results in airway hyper-responsiveness (AHR), leading to variable and excessive airway contraction. The symptoms of Non-Alcoholic Steatohepatitis (NASH) include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate.
Diagnosing Non-Alcoholic Steatohepatitis (NASH) generally includes a medical history, physical exam, and lung tests. The main tests used to help diagnose Non-Alcoholic Steatohepatitis (NASH) are the FeNO test - that measures the level of nitric oxide in the breath, which is a sign of inflammation in the lungs, and spirometry - which measures how fast one can breathe out and how much air he/she can hold in the lungs.
Organizations like the Japanese Society of Gastroenterology (JSGE), and others have published criteria for diagnosing Non-Alcoholic Steatohepatitis (NASH).
Further details related to country-based variations are provided in the report
The current treatment of Non-Alcoholic Steatohepatitis (NASH) focuses on lifestyle modifications and managing the underlying risk factors associated with the disease. These include weight loss through a combination of diet and exercise, as obesity and insulin resistance are key contributors to Non-Alcoholic Steatohepatitis (NASH) development. Additionally, managing comorbid conditions such as diabetes, dyslipidemia, and hypertension is crucial. While there is no specific medication approved for the treatment of Non-Alcoholic Steatohepatitis (NASH), several promising drugs are undergoing clinical trials, targeting different aspects of the disease including metabolic pathways, inflammation, and fibrosis. These potential therapies offer hope for the future management of Non-Alcoholic Steatohepatitis (NASH), but currently, lifestyle interventions and risk factor management remain the cornerstone of Non-Alcoholic Steatohepatitis (NASH) treatment.
With recent development in disease understanding, tailored therapies are given based on the type of Non-Alcoholic Steatohepatitis (NASH). Besides medication, lifestyle changes are recommended. In some cases, bronchial thermoplasty might be recommended.
As the market is derived using the patient-based model, the Non-Alcoholic Steatohepatitis (NASH) epidemiology chapter in the report provides historical as well as forecasted epidemiology of total diagnosed prevalent cases of Non-Alcoholic Steatohepatitis (NASH) segmented by gender and severity in Japan, from 2019 to 2032. The total diagnosed prevalent cases of Non-Alcoholic Steatohepatitis (NASH) in Japan comprised approximately 2.5 million cases in 2022 and are projected to increase during the forecast period.
The drug chapter segment of the Non-Alcoholic Steatohepatitis (NASH) report encloses a detailed analysis of Non-Alcoholic Steatohepatitis (NASH) marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands the Non-Alcoholic Steatohepatitis (NASH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Resmetirom (formerly MGL-3196) is a thyroid hormone receptor B-agonist. In December 2022, Madrigal announced topline results from the pivotal Phase III MAESTRO-NASH biopsy study of resmetirom. In addition, this study has the potential to support an additional indication for resmetirom in patients with well-compensated Non-Alcoholic Steatohepatitis (NASH) cirrhosis.
Efruxifermin (EFX), formerly AKR-001, is Akero's lead product candidate for Non-Alcoholic Steatohepatitis (NASH). EFX is designed to offer convenient once-weekly SC dosing. EFX is currently being evaluated in two Phase II clinical trials in patients with biopsy-confirmed F1-F3 and F4 Non-Alcoholic Steatohepatitis (NASH) patients.
Note: Detailed emerging therapies assessment will be provided in the final report of Non-Alcoholic Steatohepatitis (NASH).
The most popular drug classes used to treat Non-Alcoholic Steatohepatitis (NASH) include antivirals, antibiotics, antifibrotics, etc. For individuals with severe decompensated cirrhosis, early antiviral therapy is crucial. Antiviral therapy for Chronic Hepatitis B's primary objective is to reduce hepatic dysfunction and save patients from death. Interferon alpha (IFN) and nucleos(t)ide analogs are antiviral medications that are clinically used.
To date, no drug has received approval from FDA, EMA, or PMDA (Pharmaceuticals and Medical Devices Agency) for treating Non-Alcoholic Steatohepatitis (NASH). The current front-line treatment includes lifestyle modifications, such as diet and exercise. Aside from lifestyle modifications, additional treatment options for Non-Alcoholic Steatohepatitis (NASH) have included off-label use of vitamin E and anti-diabetes agents (e.g., pioglitazone and liraglutide). Because of the complexity of the different potential pathways involved in the pathogenesis of Non-Alcoholic Steatohepatitis (NASH), treatment may have to target several key elements in cellular and molecular events to achieve meaningful results.
The launch of emerging therapies, such as Resmetirom (Madrigal Pharmaceuticals, Inc.) Efruxifermin (Akero Therapeutics, Inc), and others are expected to impact the market positively.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, for BIO89-100 (Pegozafermin), in Japan we expect the drug uptake to be slow-medium with a probability-adjusted peak share of around 3%, and years to the peak is expected to be 7 years from the year of launch.
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Non-Alcoholic Steatohepatitis (NASH) emerging therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Non-Alcoholic Steatohepatitis (NASH) evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from the Department of Gastroenterology, Kobe Asahi Hospital; Liver Center, Saga University Hospital, Saga University, Saga, Japan; The Japanese Society of Gastroenterology (JSGE), Tokyo, and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in Japan. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Non-Alcoholic Steatohepatitis (NASH) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
The cost of newly approved medications is usually high; patients can escape from proper treatment or opt for off-label and cheap medications. It affects access to newly launched medications in the market, and reimbursement is crucial. Often, the decision to reimburse comes down to the drug's price relative to the benefit it produces in treated patients. Market access and reimbursement options can differ depending on regulatory status, target population size, care setting, unmet need, the magnitude of incremental benefit claims, and costs.
The days of fee-for-service medicine may soon be over, and the healthcare market is steadily moving toward value-based payment models. In most of the country, insurance carriers are increasingly assembling narrow provider networks to try and rein in costs.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.